The estimated Net Worth of David R. Horn is at least $1.64 Million dollars as of 6 February 2024. Mr Horn owns over 12,684 units of Seer stock worth over $773,623 and over the last 7 years he sold SEER stock worth over $308,775. In addition, he makes $554,293 as Exec. VP & Chief Financial Officer at Seer.
Mr has made over 15 trades of the Seer stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 12,684 units of SEER stock worth $20,041 on 6 February 2024.
The largest trade he's ever made was exercising 28,818 units of Seer stock on 6 December 2021 worth over $99,998. On average, Mr trades about 7,417 units every 127 days since 2017. As of 6 February 2024 he still owns at least 480,511 units of Seer stock.
You can see the complete history of Mr Horn stock trades at the bottom of the page.
David R. Horn is the Exec. VP & Chief Financial Officer at Seer.
As the Exec. VP & Chief Financial Officer of Seer, the total compensation of Mr Horn at Seer is $554,293. There are 3 executives at Seer getting paid more, with Dr. Omid C. Farokhzad Ph.D., M.D. having the highest compensation of $972,082.
Mr Horn is 53, he's been the Exec. VP & Chief Financial Officer of Seer since . There are no older and 5 younger executives at Seer.
David's mailing address filed with the SEC is C/O SEER, INC., 3800 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY, CA, 94065.
Over the last 7 years, insiders at Seer have traded over $150,878,393 worth of Seer stock and bought 1,798,420 units worth $33,507,980 . The most active insiders traders include Omid Farokhzad, Terrance Mcguire, and Growth Fund Limited Partner.... On average, Seer executives and independent directors trade stock every 60 days with the average trade being worth of $227,813. The most recent stock trade was executed by Dipchand Nishar on 14 June 2024, trading 12,109 units of SEER stock currently worth $21,554.
Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the secrets of the proteome. It develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that allows researchers to conduct proteomic studies in therapeutic and diagnostic research, and clinical trials. The company intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It has a collaboration agreement with Discovery Life Sciences, LLC. and the Salk Institute for Biological Studies. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
Seer executives and other stock owners filed with the SEC include: